Breaking News Instant updates and real-time market news.

TSLA

Tesla

$196.61

-4.39 (-2.18%)

, NVDA

Nvidia

$66.85

-0.49 (-0.73%)

15:13
10/10/16
10/10
15:13
10/10/16
15:13

Tesla may increase lead in ADAS with 'Tesla Vision,' Electrek reports

Tesla (TSLA) may increase its lead in semi-autonomous or advanced driver assistance systems, or ADAS, with "Tesla Vision," Electrek reports. The program is an end-to-end computer vision system built with NVIDIA'S (NVDA) CUDA, the report notes. Tesla first note the existence of the program when responding to claims made by Mobileye (MBLY), which used to be the car maker's partner for the vision system of the Autopilot, the report notes. "Tesla Vision" is not a system on a chip, or SoC, but rather an end-to-end computer vision framework, the report notes. Reference Link

TSLA

Tesla

$196.61

-4.39 (-2.18%)

NVDA

Nvidia

$66.85

-0.49 (-0.73%)

MBLY

Mobileye

$41.04

0.24 (0.59%)

  • 14

    Nov

TSLA Tesla
$196.61

-4.39 (-2.18%)

10/06/16
10/06/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Neutral from Buy at Goldman with analyst David Tamberrino saying he sees incremental risk to Tesla's business related to management's willingness to deploy capital for M&A, and he believes that any delay in the company's new Model 3 launch will be detrimental to shares. 2. JPMorgan (JPM) downgraded to Hold from Buy at Sandler O'Neill with analyst Jeffery Harte citing relative share outperformance. 3. Abercrombie & Fitch (ANF) downgraded to Sector Weight from Overweight at KeyBanc with analyst Jessica Schmidt saying the elevated promotions add to other headwinds, including the fact that the teen space is "overstored" and faces soft consumer demand and weak tourism. 4. American Express (AXP) downgraded to Reduce from Neutral at Nomura with analyst Bill Carcache saying the combination of weaker than expected revenues and higher than expected expenses will weigh on the shares. 5. Lowe's (LOW) downgraded to Neutral from Buy at Cleveland Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/16
GSCO
10/06/16
NO CHANGE
GSCO
Autos and Autos Parts sector downgraded to Cautious from Neutral at Goldman
Goldman analyst David Tamberrino downgraded the Autos and Auto Parts sector to Cautious from Neutral saying the US Auto cycle peaked in 2015 and is being held up by increasing OEM incentives. The analyst said OEM earnings will decline in 2017/2018 as negative pricing and lower production pressure North American results, but expects suppliers' earnings to hold up longer. The analyst sees upside to Delphi (DLPH) and Harman (HAR) given exposure to secular growth areas and upside to Goodyear Tire (GT) given secular HVA tire growth. Tamberrino downgraded Lear (LEA) to Sell citing elevated expectations and valuation, cut BorgWarner (BWA) to Neutral on valuation, downgraded Tesla (TSLA) to Neutral on execution risk and capital deployment, and upgraded AutoNation (AN) to Neutral given a more defensive business.
10/06/16
GSCO
10/06/16
DOWNGRADE
GSCO
Neutral
Tesla downgraded to Neutral from Buy at Goldman
Goldman analyst David Tamberrino downgraded Tesla to Neutral and lowered his price target to $185 from $240. Tamberrino sees incremental risk to Tesla's business related to management's willingness to deploy capital for M&A, and he believes that any delay in the company's new Model 3 launch will be detrimental to shares. The analyst said there is room for downward estimate revisions as volume ramps slower and spending grows. Tamberrino's 2016 earnigns estimate of (59c) is above the Street's (93c), but estimates for 2017 through 2019 are on average 48% below consensus.
10/03/16
OPCO
10/03/16
NO CHANGE
OPCO
Perform
Review process of SolarCity acquisition may be delayed, says Oppenheimer
Oppenheimer analyst Colin Rusch believes the SEC review process of Tesla's (TSLA) acquisition of SolarCity (SCTY) could be delayed due to recent activity, especially new litigation. Further, the analyst believes extension to the timeline is likely to work against the deal given the risk of ongoing "collaboration to trigger gun-jumping rules." Rusch reiterates a Perform rating on Tesla's shares.
NVDA Nvidia
$66.85

-0.49 (-0.73%)

10/03/16
BOFA
10/03/16
NO CHANGE
Target $80
BOFA
Buy
NVIDIA price target raised to $80 from $72 at BofA/Merrill
BofA/Merrill analyst Vivek Arya raised NVIDIA's price target to $80 from $72 following checks. The analyst said its survey indicates NVIDIA is maintaining an 80% share with its GTX 1060 card with 70% higher content versus last year, Deep Learning could drive upside as emerging applications take hold, and the company has potential $4 in earnings power over the next 3-4 years, higher than his previous $3 estimate. Arya rates NVIDIA a Buy and a top pick.
09/20/16
RHCO
09/20/16
INITIATION
RHCO
Neutral
NVIDIA initiated at SunTrust
As noted earlier, SunTrust initiated NVIDIA with a Neutral rating. Analyst William Stein thinks the stock will be boosted over the long-term by the proliferation of workload acceleration and artificial intelligence in data centers and automobiles. However, he thinks that the company's revenue growth appears to be peaking, as the outlook for its professional visualization, OEM, and IP end markets is negative, according to the analyst. He says that these end markets represent 22% of its sales.
09/20/16
SUSQ
09/20/16
INITIATION
Target $66
SUSQ
Neutral
NVIDIA initiated with a Neutral at Susquehanna
Susquehanna analyst Christopher Rolland initiated NVIDIA with a Neutral and a $66 price target due to valuation.
09/19/16
RHCO
09/19/16
INITIATION
Target $59
RHCO
Neutral
NVIDIA initiated with a Neutral at SunTrust
SunTrust analyst William Stein initiated NVIDIA with a Neutral and a $59 price target saying shares are failry valued.
MBLY Mobileye
$41.04

0.24 (0.59%)

09/20/16
RHCO
09/20/16
INITIATION
RHCO
Buy
Mobileye initiated at SunTrust
As noted earlier, SunTrust initiated coverage of Mobileye with a Buy rating and a $63 price target. Analyst William Stein thinks that the company "will sustain its rapid revenue growth and high margins through 2019." Stein says that Mobileye only needs to retain a "modest share" of the autonomous driving market to enable its revenue to continue to quickly increase. The analyst thinks that the company's 2019 guidance, which implies compound annual revenue growth of 46%, is "reliable," partly due to "predictable" selling prices and "predictable design ramps."
09/19/16
RHCO
09/19/16
INITIATION
Target $63
RHCO
Buy
Mobileye initiated with a Buy at SunTrust
SunTrust initiated Mobileye with a Buy and a $63 price target.
08/31/16
DBAB
08/31/16
NO CHANGE
Target $72
DBAB
Buy
Mobileye 2019 outlook more solid than perceived, says Deutsche Bank
After meeting with management, Deutsche Bank analyst Rod Lache says Mobileye's 2019 outlook is "more solid than widely perceived." Management noted that automated emergency breaking will become standard on many new launches starting in 2018, which should reduce volatility associated with assumptions for option "take rates," Lache tells investors in a research note. He keeps a Buy rating on Mobileye with a $72 price target.
08/24/16
BARD
08/24/16
NO CHANGE
BARD
Outperform
Baird remains buyer of both Delphi and Mobileye
Baird analyst David Lelker said he remains a buyer of both Delphi (DLPH) and Mobileye (MBLY) following their announcement of a partnership to develop technology for full autonomous driving. The combination forms one of the most formidable collections of technologies needed for self-driving cars, said Lelker, who added that both remain among his top ideas. The analyst reiterated his Outperform rating on both Delphi and Mobileye shares.

TODAY'S FREE FLY STORIES

HEES

H&E Equipment

$26.97

-0.2 (-0.74%)

07:04
09/26/17
09/26
07:04
09/26/17
07:04
Initiation
H&E Equipment initiated  »

H&E Equipment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOG

Northern Oil and Gas

$0.94

0.093 (10.98%)

07:04
09/26/17
09/26
07:04
09/26/17
07:04
Hot Stocks
Northern Oil and Gas announces settlement with former CEO »

Northern Oil and Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$83.14

0.26 (0.31%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Hot Stocks
Breaking Hot Stocks news story on Darden »

Darden reports Q1 Olive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BTX

BioTime

$2.72

-0.08 (-2.86%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Hot Stocks
BioTime announces 'positive' secondary, long-term data from Renevia trial »

BioTime announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MBRX

Moleculin Biotech

$2.41

-0.07 (-2.82%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Hot Stocks
Moleculin Biotech announces FDA approval of Annamycin IND »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNCA

Genocea

$5.33

0.04 (0.76%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Downgrade
Genocea rating change  »

Genocea downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

DRI

Darden

$83.14

0.26 (0.31%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Hot Stocks
Darden reports Q1 blended same-restaurant sales from legacy brands up 1.7% »

Q1 same-restaurant sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AKBA

Akebia

$17.90

0.33 (1.88%)

07:02
09/26/17
09/26
07:02
09/26/17
07:02
Hot Stocks
Breaking Hot Stocks news story on Akebia »

Akebia: Phase 2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AXON

Axovant Sciences

$24.25

-0.74 (-2.96%)

07:02
09/26/17
09/26
07:02
09/26/17
07:02
Hot Stocks
Breaking Hot Stocks news story on Axovant Sciences »

Axovant announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$83.14

0.26 (0.31%)

07:02
09/26/17
09/26
07:02
09/26/17
07:02
Earnings
Darden backs FY18 adjusted cont ops EPS view $4.38-$4.50, consensus $4.47 »

The company reaffirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AKBA

Akebia

$17.90

0.33 (1.88%)

07:02
09/26/17
09/26
07:02
09/26/17
07:02
Hot Stocks
Breaking Hot Stocks news story on Akebia »

Akebia: Phase 3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AKBA

Akebia

$17.90

0.33 (1.88%)

07:01
09/26/17
09/26
07:01
09/26/17
07:01
Hot Stocks
Akebia saya Phase 2 vadadustat study confirmed findings from previous studies »

Akebia Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

07:00
09/26/17
09/26
07:00
09/26/17
07:00
General news
FX Update: The dollar has been in rally mode »

FX Update: The dollar has…

DIS

Disney

$99.57

0.97 (0.98%)

06:59
09/26/17
09/26
06:59
09/26/17
06:59
Periodicals
Disney streams theme-park events in new prototype stores, Bloomberg says »

Walt Disney is opening…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

SPX

S&P 500

06:59
09/26/17
09/26
06:59
09/26/17
06:59
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LCI

Lannett

$17.10

-0.3 (-1.72%)

06:58
09/26/17
09/26
06:58
09/26/17
06:58
Hot Stocks
Lannett revceives approval for Dexmethylphenidate Hydrochloride Tablets »

Lannett announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$23.83

0.36 (1.53%)

06:58
09/26/17
09/26
06:58
09/26/17
06:58
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$124.53

1.29 (1.05%)

06:58
09/26/17
09/26
06:58
09/26/17
06:58
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXON

Axovant Sciences

$24.25

-0.74 (-2.96%)

06:58
09/26/17
09/26
06:58
09/26/17
06:58
Hot Stocks
Breaking Hot Stocks news story on Axovant Sciences »

Axovant Sciences trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$35.50

1.72 (5.09%)

06:57
09/26/17
09/26
06:57
09/26/17
06:57
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$20.07

1 (5.24%)

06:57
09/26/17
09/26
06:57
09/26/17
06:57
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$23.21

-1.2 (-4.92%)

06:57
09/26/17
09/26
06:57
09/26/17
06:57
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$50.66

-2.87 (-5.36%)

06:56
09/26/17
09/26
06:56
09/26/17
06:56
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXX

iPath S&P 500 VIX Short-Term Futures

$41.28

0.03 (0.07%)

06:56
09/26/17
09/26
06:56
09/26/17
06:56
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$92.69

-0.14 (-0.15%)

06:55
09/26/17
09/26
06:55
09/26/17
06:55
Technical Analysis
VelocityShares Daily Inverse VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.